These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33789832)

  • 1. Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated with monocyte subsets in patients with stable coronary artery disease.
    Krychtiuk KA; Lenz M; Hohensinner P; Distelmaier K; Schrutka L; Kastl SP; Huber K; Dostal E; Oravec S; Hengstenberg C; Wojta J; Speidl WS
    J Clin Lipidol; 2021; 15(3):512-521. PubMed ID: 33789832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease.
    Hu D; Yang Y; Peng DQ
    Int J Cardiol; 2017 Jan; 227():61-65. PubMed ID: 27846466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Statin Therapy on Plasma Proprotein Convertase Subtilisin/kexin Type 9 and Sortilin Levels in Statin-Naive Patients with Coronary Artery Disease.
    Nozue T; Hattori H; Ogawa K; Kujiraoka T; Iwasaki T; Michishita I
    J Atheroscler Thromb; 2016 Jul; 23(7):848-56. PubMed ID: 26797266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.
    Werner C; Hoffmann MM; Winkler K; Böhm M; Laufs U
    Vascul Pharmacol; 2014 Aug; 62(2):94-102. PubMed ID: 24685817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study.
    Cariou B; Guérin P; Le May C; Letocart V; Arnaud L; Guyomarch B; Pichelin M; Probst V
    Diabetes Metab; 2017 Dec; 43(6):529-535. PubMed ID: 28865748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease.
    Krychtiuk KA; Kastl SP; Pfaffenberger S; Pongratz T; Hofbauer SL; Wonnerth A; Katsaros KM; Goliasch G; Gaspar L; Huber K; Maurer G; Dostal E; Oravec S; Wojta J; Speidl WS
    Atherosclerosis; 2014 Dec; 237(2):589-96. PubMed ID: 25463093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
    Sahebkar A; Simental-Mendía LE; Guerrero-Romero F; Golledge J; Watts GF
    Diabetes Obes Metab; 2015 Nov; 17(11):1042-55. PubMed ID: 26183252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy.
    Kuyama N; Kataoka Y; Takegami M; Nishimura K; Harada-Shiba M; Hori M; Ogura M; Otsuka F; Asaumi Y; Noguchi T; Tsujita K; Yasuda S
    J Am Heart Assoc; 2021 Jun; 10(11):e019525. PubMed ID: 33998287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics.
    Gauthier MS; Awan Z; Bouchard A; Champagne J; Tessier S; Faubert D; Chabot K; Garneau PY; Rabasa-Lhoret R; Seidah NG; Ridker PM; Genest J; Coulombe B
    J Clin Lipidol; 2018; 12(4):1027-1038. PubMed ID: 29699916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of small dense LDL serum levels and circulating monocyte subsets in stable coronary artery disease.
    Krychtiuk KA; Kastl SP; Pfaffenberger S; Lenz M; Hofbauer SL; Wonnerth A; Koller L; Katsaros KM; Pongratz T; Goliasch G; Niessner A; Gaspar L; Huber K; Maurer G; Dostal E; Wojta J; Oravec S; Speidl WS
    PLoS One; 2015; 10(4):e0123367. PubMed ID: 25849089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.
    Kaasenbrood L; Ray KK; Boekholdt SM; Smulders YM; LaRosa JC; Kastelein JJP; van der Graaf Y; Dorresteijn JAN; Visseren FLJ
    Heart; 2018 Oct; 104(20):1699-1705. PubMed ID: 29622600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
    Nozue T; Hattori H; Ishihara M; Iwasaki T; Hirano T; Kawashiri MA; Yamagishi M; Michishita I
    Am J Cardiol; 2013 May; 111(10):1415-9. PubMed ID: 23433768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
    JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a).
    Krychtiuk KA; Kastl SP; Hofbauer SL; Wonnerth A; Goliasch G; Ozsvar-Kozma M; Katsaros KM; Maurer G; Huber K; Dostal E; Binder CJ; Pfaffenberger S; Oravec S; Wojta J; Speidl WS
    J Clin Lipidol; 2015; 9(4):533-41. PubMed ID: 26228671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
    Cao G; Qian YW; Kowala MC; Konrad RJ
    Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):238-43. PubMed ID: 19075777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
    Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
    Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between proprotein convertase subtilisin/kexin type 9 and late saphenous vein graft disease after coronary artery bypass grafting: a cross-sectional study.
    Gao J; Wang HB; Xiao JY; Ren M; Reilly KH; Li YM; Liu Y
    BMJ Open; 2018 Jul; 8(7):e021951. PubMed ID: 29991632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.